Deciphering the Cellular Targets of Bioactive Compounds Using a Chloroalkane Capture Tag.

Phenotypic screening of compound libraries is a significant trend in drug discovery, yet success can be hindered by difficulties in identifying the underlying cellular targets. Current approaches rely on tethering bioactive compounds to a capture tag or surface to allow selective enrichment of interacting proteins for subsequent identification by mass spectrometry. Such methods are often constrained by ineffective capture of low affinity and low abundance targets. In addition, these methods are often not compatible with living cells and therefore cannot be used to verify the pharmacological activity of the tethered compounds. We have developed a novel chloroalkane capture tag that minimally affects compound potency in cultured cells, allowing binding interactions with the targets to occur under conditions relevant to the desired cellular phenotype. Subsequent isolation of the interacting targets is achieved through rapid lysis and capture onto immobilized HaloTag protein. Exchanging the chloroalkane tag for a fluorophore, the putative targets identified by mass spectrometry can be verified for direct binding to the compound through resonance energy transfer. Using the interaction between histone deacetylases (HDACs) and the inhibitor, Vorinostat (SAHA), as a model system, we were able to identify and verify all the known HDAC targets of SAHA as well as two previously undescribed targets, ADO and CPPED1. The discovery of ADO as a target may provide mechanistic insight into a reported connection between SAHA and Huntington's disease.

[1]  K. Wood,et al.  NanoBRET--A Novel BRET Platform for the Analysis of Protein-Protein Interactions. , 2015, ACS chemical biology.

[2]  Leigh A. Stoddart,et al.  Application of BRET to monitor ligand binding to GPCRs , 2015, Nature Methods.

[3]  R. Yamada,et al.  Comparison of the Reactivity of Carbohydrate Photoaffinity Probes with Different Photoreactive Groups , 2014, Chembiochem : a European journal of chemical biology.

[4]  Yuguo Zheng,et al.  Target identification of biologically active small molecules via in situ methods. , 2013, Current opinion in chemical biology.

[5]  Benjamin E. L. Lauffer,et al.  Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability , 2013, The Journal of Biological Chemistry.

[6]  P. Nordlund,et al.  Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay , 2013, Science.

[7]  Bu-shan Xie,et al.  CSTP1, a Novel Protein Phosphatase, Blocks Cell Cycle, Promotes Cell Apoptosis, and Suppresses Tumor Growth of Bladder Cancer by Directly Dephosphorylating Akt at Ser473 Site , 2013, PloS one.

[8]  Herbert Waldmann,et al.  Target identification for small bioactive molecules: finding the needle in the haystack. , 2013, Angewandte Chemie.

[9]  Marjeta Urh,et al.  SUPPLEMENTARY MATERIAL Development of a Dehalogenase-Based Protein Fusion Tag Capable of Rapid, Selective and Covalent Attachment to Customizable Ligands , 2012 .

[10]  Brock F. Binkowski,et al.  Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate , 2012, ACS chemical biology.

[11]  B. Cravatt,et al.  Fully functionalized small-molecule probes for integrated phenotypic screening and target identification. , 2012, Journal of the American Chemical Society.

[12]  Marcus Bantscheff,et al.  Chemoproteomic approaches to drug target identification and drug profiling. , 2012, Bioorganic & medicinal chemistry.

[13]  Anna K. Schrey,et al.  SAHA Capture Compound – A novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders , 2011, Proteomics.

[14]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[15]  P. Grandi,et al.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.

[16]  S. Kazmirski,et al.  Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[17]  Shin-ichi Sato,et al.  Biochemical target isolation for novices: affinity-based strategies. , 2010, Chemistry & biology.

[18]  James E. Bradner,et al.  Chemical Phylogenetics of Histone Deacetylases , 2010, Nature chemical biology.

[19]  Jack Taunton,et al.  Target Identification by Diazirine Photo‐Cross‐Linking and Click Chemistry , 2009, Current protocols in chemical biology.

[20]  Albert J R Heck,et al.  Revealing promiscuous drug-target interactions by chemical proteomics. , 2009, Drug discovery today.

[21]  C. Carlberg,et al.  Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene. , 2009, Journal of molecular biology.

[22]  G. Superti-Furga,et al.  Target profiling of small molecules by chemical proteomics. , 2009, Nature chemical biology.

[23]  J. Woska,et al.  Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling. , 2009, Biochemical pharmacology.

[24]  A. Kawamura,et al.  Binding is not enough: flexibility is needed for photocrosslinking of Lck kinase by benzophenone photoligands. , 2008, Bioorganic & medicinal chemistry.

[25]  B. Leslie,et al.  Identification of the cellular targets of bioactive small organic molecules using affinity reagents. , 2008, Chemical Society reviews.

[26]  Marjeta Urh,et al.  HaloTag: a novel protein labeling technology for cell imaging and protein analysis. , 2008, ACS chemical biology.

[27]  Andrew Emili,et al.  Proteomic methods for drug target discovery. , 2008, Current opinion in chemical biology.

[28]  B. Cravatt,et al.  Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. , 2008, Journal of the American Chemical Society.

[29]  Gerhard Dürnberger,et al.  Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. , 2007, Blood.

[30]  P. Marks,et al.  Histone Deacetylase Inhibitors: Overview and Perspectives , 2007, Molecular Cancer Research.

[31]  J. Dominy,et al.  Discovery and Characterization of a Second Mammalian Thiol Dioxygenase, Cysteamine Dioxygenase* , 2007, Journal of Biological Chemistry.

[32]  B. Cravatt,et al.  Activity-based probes for proteomic profiling of histone deacetylase complexes , 2007, Proceedings of the National Academy of Sciences.

[33]  T. A. Taton,et al.  Site-specific, covalent attachment of proteins to a solid surface. , 2006, Bioconjugate chemistry.

[34]  Anna E Speers,et al.  Profiling enzyme activities in vivo using click chemistry methods. , 2004, Chemistry & biology.

[35]  Leslie M Thompson,et al.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Sawsan Youssef,et al.  Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine , 2002, Nature Medicine.

[37]  C. Johnson,et al.  A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Brent Analysis of Protein‐Protein Interactions , 1998, Current protocols in protein science.

[39]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[40]  Khusru Asadullah,et al.  What makes a good drug target? , 2012, Drug discovery today.

[41]  P. Chaumet‐Riffaud,et al.  A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. , 1999, British journal of clinical pharmacology.